Holen Sie sich die Stockscreener-App
7.49
0.40%
0.03
Handel nachbörslich:
7.54
0.05
+0.67%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$7.46
Offen:
$7.76
24-Stunden-Volumen:
3.31M
Relative Volume:
0.71
Marktkapitalisierung:
$1.23B
Einnahmen:
$596.34M
Nettoeinkommen (Verlust:
$-87.84M
KGV:
-12.54
EPS:
-0.5975
Netto-Cashflow:
$-97.62M
1W Leistung:
-4.95%
1M Leistung:
-15.65%
6M Leistung:
-23.73%
1J Leistung:
+0.27%
1-Tages-Spanne:
$7.49
$7.82
1-Wochen-Bereich:
$7.45
$8.1799
52-Wochen-Spanne:
$6.20
$11.97
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
7.49 | 1.23B | 596.34M | -87.84M | -97.62M | -0.5975 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-08-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-08-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Eingeleitet | Citigroup | Sell |
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
NVAX|Novavax Inc|Price:7.460|Chg%:-0.365 - TradingKey
Novavax Inc (NVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue - Stocktwits
Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? - Stocktwits
Novavax Inc (NVAX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NVAX Stock Rises Overnight Ahead Of Q4 Print With Pfizer Tailwinds — Analyst Warns Of 20% Crash - Stocktwits
Novavax Inc (NVAX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Novavax Inc (NVAX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Novavax, Inc. Revenue Breakdown – NASDAQ:NVAX - TradingView
Novavax Inc (NVAX) Institutional Confidence - TradingKey
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax Inc (NVAX) Fundamental & Financial Data - Stocktwits
(NVAX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Novavax Inc (NVAX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax Inc. Stock Sheds 4.0%, Underperforms Peers - webull.com
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NVAX) Stock Analysis: Potential Upside of 79.10% Amidst Challenging Financial Metrics - DirectorsTalk Interviews
NVAX Stock Is Rising Even After A Revenue Collapse – Here’s The Catch - Stocktwits
Novavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
NVAX stock trades in a wide range as Novavax works through Covid vaccine transition - AD HOC NEWS
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Novavax Q4 Earnings Preview: Wall Street Expects Wider Losses Amid Diversification Efforts - Stocktwits
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Robert Edward Walker Net Worth (2026) - GuruFocus
Novavax options trading jumps to highest in months By Investing.com - Investing.com Nigeria
Novavax options trading jumps to highest in months - Investing.com
Enterprise value to EBIT forward of Novavax, Inc. – BMV:NVAX - TradingView
Novavax, Inc. (NVAX) is a trending stock: Facts to know before betting on it - MSN
Novavax (NVAX) Leaves Russell Growth Indexes, Is The 32% Undervaluation Case Convincing? - Yahoo Finance
Novavax (NVAX) Dropped From Major Russell Growth Indices And Why It Matters - Yahoo Finance
Novavax (NVAX) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Novavax Inc. stock outperforms competitors despite losses on the day - MarketWatch
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Novavax Inc updates Covid-19 vaccine plans as investors weigh long-term prospects - ad-hoc-news.de
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study - TradingView
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Does Novavax’s (NVAX) Russell Exit Quietly Recast Its Partnership-Driven, Royalty-Focused Equity Story? - Sahm
NOVAVAX INC (NVAX) Stock Chart - ChartMill
Novavax (NVAX) Stock Moves 1.36%: What You Should Know - Yahoo Finance
Novavax Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
(NVAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):